Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells.
Helicobacter pylori is a major etiological agent in gastroduodenal disorders. The adhesion of H. pylori to gastric epithelial cells is the initial step of H. pylori infection. Inhibition of H. pylori adhesion is thus a therapeutic target in the prevention of H. pylori infection. We have reported that rebamipide and ecabet sodium, mucoprotective antiulcer agents, independently inhibit H. pylori adhesion. However, the antiadhesion activity of each antiulcer agent was incomplete. Experiments were performed to evaluate the combined effect of rebamipide and ecabet sodium on H. pylori adhesion to gastric epithelial cells. MKN-28 and MKN-45 cells, derived from human gastric carcinomas, were used as target cells. Twelve clinical isolates of H. pylori were used in this study. We evaluated the effects of rebamipide and ecabet sodium, individually and in combination, on H. pylori adhesion to target cells quantitatively using our previously established enzyme-linked immunosorbent assay. Rebamipide and ecabet sodium each partially inhibited H. pylori adhesion. In contrast, adhesion was almost completely inhibited by pretreating target cells and H. pylori with the combination of rebamipide and ecabet sodium. Our studies suggest that the synergistic antiadhesion activity of rebamipide and ecabet sodium is greater than that of each antiulcer agent alone.
Hayashi
S
S
Department of Microbiology, Jichi Medical School, Tochigi, Japan. shunhaya@jichi.ac.jp
Sugiyama
T
T
Yokota
K
K
Isogai
H
H
Isogai
E
E
Shimomura
H
H
Oguma
K
K
Asaka
M
M
Hirai
Y
Y
D045784:Abietanes; D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001422:Bacterial Adhesion / Q000187:drug effects*; D002460:Cell Line; D004224:Diterpenes / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D004847:Epithelial Cells / Q000382:microbiology*; D016480:Helicobacter pylori / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy / Q000378:metabolism
D045784:Abietanes; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D015363:Quinolones; C061681:ecabet; C052785:rebamipide; D000409:Alanine